PitchSend

argenx SE Investor Day Presentation Deck

Bullous Pemphigoid: Expanding the Skin Franchise argenx Autoimmune Blistering Diseases Autoantibody Driven Convincing Rationale Unmet Patient Needs Primary Endpoint Pemphigus DSG1 and DSG3 Pemphigoid BP180 and BP230 IVlg, PLEX, Immunoadsorption demonstrate role of IgG Fast-acting, tolerable therapies; ability to taper corticosteroids Complete or partial remission off corticosteroids Registrational trial to start by end of year in parallel to ongoing pemphigus trial 11

View entire presentation